Kenney & Ross Limited, Nova Scotia   Report issue

For profit Phase 2
Founded: Port Saxon Canada (1945)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2007
NCT01215903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

Kenney & Ross Limited, Nova Scotia (in-kind support: Fish gelatin)

Active Ingredients

Drugs in Phase 2 Trials (2)

fish oil (Omegavan) (1 trial)

icosapent ethyl (vascepa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Insulin Resistance (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2